Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Capita reiterates outlook, extends credit facility

(Sharecast News) - Capita has extended its £250m credit facility, the British outsourcer confirmed on Wednesday, as it reiterated its full-year guidance. The London-listed firm, which provides outsourcing services to clients across the public and private sectors, said it had extended the maturity date of the revolving credit facility by a year, to 31 December 2027.

The facility has been arranged by eight lenders, two of whom - Royal Bank of Canada and ABN Amro - are new members of the syndicate.

The update came as Capita confirmed its full-year financial guidance for "broadly" flat revenues and an operating margin improvement weighted to the second half of the year.

"We continue to expect the group to be free cash flow positive from the end of 2025," it added.

Capita is due to post interim numbers on 5 August.

Ahead of that, it published financial results for the first half of 2024 under its revised operating structure.

Group adjusted revenues were £1.2bn, and adjusted operating profits were £54.5m. The biggest contributor to both sales and profits was the public service division, with profits of £47.4m on revenues of £685.6m.

Under the revised operating structure, Capita's experience arm is now reported as three distinct subdivisions: contact centre, pensions and regulated services.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.